The success of an experimental prostate cancer treatment is an example of how academic research centers are playing a larger role in drug development, the Wall Street Journal reports.

Infections are a common cause of complications in cancer patients. Now a Memorial Sloan-Kettering research team finds that a commonly prescribed antibiotic could increase susceptibility to a bacterial infection.

Years of innovative research, technology development, and facility expansion at Memorial Sloan-Kettering have led to several new experimental treatments for people with cancer.

German-born cancer biologist Hans-Guido Wendel is taking advantage of transformative advances in genomics technology to understand key genetic abnormalities in leukemia and lymphoma.

Memorial Sloan-Kettering scientists, physicians, and administrators are developing and commercializing research discoveries to generate more-effective and affordable cancer treatments.

Scientists have generated a compound that could potentially be used to create a new type of pain medication that may prevent the side effects of currently available painkillers.

Memorial Sloan-Kettering notes with sadness the death of Lloyd J. Old, who was internationally recognized as one of the founders and standard bearers of the field of tumor immunology.